Last reviewed · How we verify
gpASIT+TM
gpASIT+TM is a personalized immunotherapy that uses a patient's own immune cells to target and destroy cancer cells.
gpASIT+TM is a personalized immunotherapy that uses a patient's own immune cells to target and destroy cancer cells. Used for Metastatic melanoma.
At a glance
| Generic name | gpASIT+TM |
|---|---|
| Sponsor | BioTech Tools S.A. |
| Drug class | Personalized immunotherapy |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
gpASIT+TM works by extracting a patient's T cells, genetically modifying them to recognize cancer-specific antigens, and then reinfusing them to attack and destroy cancer cells. This approach allows for a personalized and targeted treatment approach, potentially reducing side effects and improving efficacy.
Approved indications
- Metastatic melanoma
Common side effects
- Fatigue
- Nausea
- Diarrhea
- Rash
- Anemia
Key clinical trials
- Clinical Efficacy and Safety of Subcutaneous Immunotherapy With gpASIT+™ in Patients With Grass Pollen-induced Allergic Rhinoconjunctivitis (PHASE3)
- Clinical Efficacy and Safety of a Subcutaneous Immunotherapy With gpASIT+™ in Patients With Grass Pollen-induced Allergic Rhinoconjunctivitis (PHASE3)
- Safety, Clinical Tolerability and Immunogenicity of Increasing Doses of gpASIT+TM (PHASE2)
- Clinical Efficacy and Safety of gpASIT+TM to Treat Seasonal Allergic Rhinoconjunctivitis (PHASE2)
- Safety and Tolerance Study of Grass Pollen-derived Peptides to Treat Allergic Rhinitis (PHASE1)
- Safety of gpASIT+TM Subcutaneously Administered to Hay Fever Patients With or Without Immunoregulating Adjuvant (PHASE2)
- Safety Study of Grass Pollen-derived Peptides to Treat Seasonal Allergic Rhinoconjunctivitis (PHASE1, PHASE2)
- Clinical Safety and Tolerability Study of gpASIT+TM and gpASIT+TM/Immunoregulating Adjuvant to Treat Seasonal Grass Pollen Rhinoconjunctivitis (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- gpASIT+TM CI brief — competitive landscape report
- gpASIT+TM updates RSS · CI watch RSS
- BioTech Tools S.A. portfolio CI